LEADER 05254nam 22005775 450 001 9910491028203321 005 20251204111517.0 010 $a3-030-68858-5 010 $a9783030688570 024 7 $a10.1007/978-3-030-68858-5 035 $a(CKB)4100000011979428 035 $a(MiAaPQ)EBC6675945 035 $a(Au-PeEL)EBL6675945 035 $a(OCoLC)1260347846 035 $a(PPN)258065451 035 $a(DE-He213)978-3-030-68858-5 035 $a(EXLCZ)994100000011979428 100 $a20210707d2021 u| 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAtlas of Clinical PET-CT in Treatment Response Evaluation in Oncology /$fedited by Stefano Fanti, Gopinath Gnanasegaran, Ignasi Carrió 205 $a1st ed. 2021. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2021. 215 $a1 online resource (483 pages) 225 1 $aMedicine Series 311 08$a3-030-68857-7 327 $aPART I General Chapters: Introduction to Treatment response evaluation: Science and Practice -- CT in Treatment response evaluation ? Overview -- MRI & Diffusion weighted MRI in Treatment response evaluation- Overview -- PET & PET-CT in Treatment response evaluation-Overview -- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in post-surgical setting -- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in chemotherapy setting -- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in radiation oncology -- Conventional Radiological Techniques and PET-CT in Treatment response evaluation in Immunotherapy settings -- Treatment response evaluation of bone metastases using 18F-NaF -- How to report PET-CT scans in post therapy scenarios: Do?s and don?ts -- PART II Atlas Articles: 18F-FDG & Non FDG PET-CT in Treatment response evaluation in Head and neck cancer -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in lung cancer -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in neuro-oncology -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in hepatobiliary cancer -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in gastroesophageal cancer -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in Lymphoma and Non-hodgkins lymphoma -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in breast cancer -- 18F-FDG, 18F-Choline & 68Ga-PSMA PET-CT in Treatment response evaluation in prostate cancer -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in gynaecological cancers -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in colorectal cancer -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in soft tissue sarcomas -- FDG & Non FDG PET-CT in Treatment response evaluation in malignant melanoma -- 18F-FDG & Non FDG PET-CT in Treatment response evaluation in myeloma -- FDG PET-CT & 18F-NaF in Treatment response evaluation in bone metastases and bone tumours -- 18F-FDG & Non FDG PET-CT in Assessment of treatment response in paediatric oncology -- 68Ga-DOTA PET-CT in Treatment response evaluation in NETs -- 18F-DOPA PET-CT in Treatment response evaluation -- 18F-FLT PET-CT in Treatment response evaluation -- Brain PET-CT in Treatment response evaluation. 330 $aThis text atlas is a superb guide to the use of PET-CT for the evaluation of treatment response in oncology patients based on its ability to assess tumor metabolic status. The first part of the book explains the role of PET-CT in response evaluation in different treatment settings. For comparison, overviews of the value and limitations of CT alone, PET alone, and anatomical and functional MRI are included. Guidance is also provided on the reporting of PET-CT scans in post-therapy scenarios. The second part of the book describes and illustrates the use of PET-CT with FDG and other tracers to assess the treatment response of malignancies at different anatomic sites. Featuring a wealth of images, informative case-based discussion, and evidence-based teaching points, these disease-specific chapters clearly demonstrate the key role that PET-CT can play in distinguishing early responders from patients who are non-responders or are resistant to treatment. Prompt and accurate evaluation of treatment response is vital as we enter the era of individualized medicine, and this atlas will persuade readers of the considerable advantages of PET-CT over conventional radiological and clinical methods. 410 0$aMedicine Series 606 $aNuclear medicine 606 $aOncology 606 $aNuclear Medicine 606 $aOncology 615 0$aNuclear medicine. 615 0$aOncology. 615 14$aNuclear Medicine. 615 24$aOncology. 676 $a616.99407575 702 $aFanti$b Stefano 702 $aGnanasegaran$b Gopinath 702 $aCarrio?$b Ignasi 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910491028203321 996 $aAtlas of Clinical PET-CT in Treatment Response Evaluation in Oncology$92587271 997 $aUNINA